In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.
As 2025 unfolds, we'll witness a growth in how AI disrupts test automation by streamlining repetitive tasks such as regression testing and defect detection. Expect a surge in AI tools that predict ...